Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.
Genmab acquires the Dutch biotech for $8bn.
BNT329 enters the clinic, as do four other new ADCs.
Four more failed tiragolumab trials, including Imbrave-152, will feature.
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
